<DOC>
	<DOCNO>NCT03103074</DOCNO>
	<brief_summary>Randomized double blind placebo control pilot study/proof concept-study see intradermal injection Botulinum toxin B effective treatment Hidradenitis suppurativa</brief_summary>
	<brief_title>Pilot Study Botulinum Toxin B Treatment Hidradenitis Suppurativa</brief_title>
	<detailed_description>Twenty patient hidradenitis suppurativa enrol randomised treatment either botulinum toxin B placebo ( saline ) affect area . Intervention record data perform every three month . After three month , patient receive active substance . After six month , randomization reveal . Patients clinical improvement give opportunity continue treatment additional six month .</detailed_description>
	<mesh_term>Hidradenitis</mesh_term>
	<mesh_term>Hidradenitis Suppurativa</mesh_term>
	<mesh_term>Botulinum Toxins</mesh_term>
	<mesh_term>rimabotulinumtoxinB</mesh_term>
	<mesh_term>Botulinum Toxins , Type A</mesh_term>
	<criteria>Patients active hidradenitis stage IIII accord Hurleys classification . Patients refer dermatology outpatient clinic patient already establish treatment program , indication new different treatment , surgical intervention . Patients must typical affection disease either axilla , groin , and/or perigenital/perianal area Patients need emergency medical surgical treatment hidradenitis exclude disease quiet , control phase . Pregnant lactating , well patient neurological disease myasthenia gravis motor neuron disease .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>botulinum toxin</keyword>
</DOC>